View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 9, 2022

YishengBio obtains UAE, Philippines approvals for Covid-19 vaccine trials

The recombinant vaccine has potential prophylactic and therapeutic benefits against the Covid-19 infection.

YishengBio has received approval from the United Arab Emirates (UAE) and the Philippines regulatory authorities for conducting Phase II/III clinical trials for its PIKA recombinant Covid-19 vaccine.

Designed to be multi-country and multi-centre, these trials will assess the safety, efficacy, and immunogenicity of the vaccine as a booster injection in subjects who were given two or more inactivated Covid-19 vaccine doses.

The trial will enrol 9,300 subjects in the UAE, the Philippines, and Pakistan.

The recombinant Covid-19 vaccine comprises PIKA adjuvant and S protein antigens and has potential prophylactic and therapeutic benefits against the infection.

In pre-clinical studies, the vaccine showed to be capable of sustaining two year-long high neutralising antibody levels against a broad range of the Covid-19 virus variants, including Omicron BA.2, BA.4/5.

YishengBio chairman and project leader Yi Zhang said: “The initiation of the phase II/III clinical trials in multi countries will accelerate the clinical development of PIKA recombinant Covid-19 vaccine candidate to a new level.

“This vaccine candidate has the potential to become a universal vaccine against the swiftly mutating SARS-CoV-2 virus worldwide.

“Equally important, our newly constructed manufacturing plant dedicated to the commercialisation of PIKA recombinant Covid-19 vaccine was recently granted the drug manufacturing certificate by the China’s National Medical Products Administration (NMPA).”

Interim data from the Phase I trial the of PIKA Covid-19 vaccine in the UAE showed that subjects who received a low dose of 5ug per injection attained high neutralising antibody levels against all variants of the SARS-CoV-2 virus in the prime vaccination regimen, and in booster doses.

These subjects completed two inactivated vaccine doses.

In Phase I clinical trials, the vaccine showed a good safety profile.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena